Revenues: | |
Product sales | 597.51K |
Research and development | 129.19K |
Total revenues | 741.81K |
Costs and Expenses: | |
Costs of goods sold | 255.11K |
Research and development | 14.53M |
Sales and marketing | 215.86K |
General and administrative | 691.58K |
Total costs and expenses | 15.69M |
Operating loss | -14.95M |
Interest and other income | 85.21K |
Foreign currency transaction gain | 2.46K |
Loss before income tax expense | |
Income tax (expense) | 0 |
Net (loss) | -16.23M |
Less net (loss) attributable to noncontrolling interest | -31.05K |
Net (loss) attributable to Immunomedics, Inc. stockholders | -16.2M |
(Loss) per common share attributable to Immunomedics, Inc. stockholders, (basic and diluted) | -0.17 |
Weighted average shares used to calculate loss per common share, (basic and diluted) | |
Comprehensive (loss): | |
Net (loss) | |
Other comprehensive (loss) income, net of tax: | |
Foreign currency translation adjustments | |
Unrealized gain on securities available for sale - net | -32.61K |
Other comprehensive (loss) income | |
Comprehensive (loss) | -16.19M |